Vor Biopharma Inc Stock

Robert ang, vor’s president and chief executive officer, will be participating in a fireside chat at the jmp securities hematology and oncology summit. This suggests a possible upside of 174.0% from the stock's current price.

Vor Biopharma Company Profile Stock Performance Earnings Pitchbook

1 day) and price target of 14.10 usd.

Vor biopharma inc stock. The schedule 13d indicates that the investor holds (or held) more than 5% of. Vor to participate in the jmp securities hematology and oncology summit. Their forecasts range from $19.00 to $60.00.

On average, they anticipate vor biopharma's share price to reach $46.83 in the next year. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. The company is engaged in combining a novel patient engineering approach with targeted therapies to provide solution for patients suffering from hematological malignancies.

It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. Vor | complete vor biopharma inc. The average vor stock price target is 51.50 with a high estimate of 60.00 and a low estimate of 40.00.

Engages in developing cell therapies for treating cancer. Vor biopharma inc is primarely in the business of biological products (no diagnostic substances). Get the latest stock news for nasdaq companies, press releases, financial disclosures and multimedia content, for day traders, investment community, individual investors and the general public.

The stock opened at $42.02 was jumped 104.9% in early action. Change the normal | expose the cancer. Vor biopharma inc nasdaq updated dec 3, 2021 11:03 pm.

Vor biopharma general information description. Vor biopharma insider sold over $5.0m in company stock. Vor biopharma inc stock price forecast for further price development up to 3.79% (time horizon:

For financial reporting, their fiscal year ends on december 31st. Changing the paradigm of cancer thinking. Vor biopharma inc is a clinical stage cell therapy company.

It is developing vor33, an ehsc product candidate that is in preclinical development to treat acute myeloid leukemia (aml) and other hematological malignancies. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. Is incorporated in the state of delaware.

Kush parmar, insider at vor biopharma (nasdaq:vor), made a large insider sell on november 16, according to a new sec filing. Vor biopharma inc (us:vor) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. It is developing vor33, an ehsc product candidate that is in preclinical development to treat acute myeloid leukemia (aml) and other hematological malignancies.

Vor vor biopharma inc — stock price and discussion | stocktwits. Vor biopharma inc complete an upsized $176.9 million ipo, offering 9.83 million shares at $18 each. The company's products include vor33.